IRVINE, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that it will release financial results for the three and 12 months ended December 31, 2016 after market close on Wednesday, February 22, 2017.  CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.

Live Call:U.S.:(866) 634-2258
 International:(330) 863-3454
Live Webcast:
 The webcast replay will be archived for 30 days
Replay:U.S.:(855) 859-2056
 International:(404) 537-3406
 The telephone replay will be available for seven days

About CombiMatrix Corporation

CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care.  CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies.  Our testing focuses on advanced technologies, including single nucleotide polymorphism (“SNP”) chromosomal microarray analysis (“CMA”), next generation sequencing (“NGS”), fluorescent in situ hybridization (“FISH”) and high resolution karyotyping.  Additional information about CombiMatrix is available at or by calling (800) 710-0624.

Company Contact:				
Mark McDonough				
President & CEO, CombiMatrix Corporation  
(949) 753-0624 					
Investor Contact:
Jody Cain
(310) 691-7100